Cited by 578Autophagy in Disease and TherapyGenetic Neurodegenerative DiseasesAlzheimer's disease research and treatments

Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies

Sarkar, S, Ravikumar, B, Floto, R A, Rubinsztein, D C·2009·Cell Death & Differentiation

Abstract

The formation of intra-neuronal mutant protein aggregates is a characteristic of several human neurodegenerative disorders, like Alzheimer's disease, Parkinson's disease (PD) and polyglutamine disorders, including Huntington's disease (HD). Autophagy is a major clearance pathway for the removal of mutant huntingtin associated with HD, and many other disease-causing, cytoplasmic, aggregate-prone proteins. Autophagy is negatively regulated by the mammalian target of rapamycin (mTOR) and can be induced in all mammalian cell types by the mTOR inhibitor rapamycin. It can also be induced by a recently described cyclical mTOR-independent pathway, which has multiple drug targets, involving links between Ca(2+)-calpain-G(salpha) and cAMP-Epac-PLC-epsilon-IP(3) signalling. Both pathways enhance the clearance of mutant huntingtin fragments and attenuate polyglutamine toxicity in cell and animal models. The protective effects of rapamycin in vivo are autophagy-dependent. In Drosophila models of various diseases, the benefits of rapamycin are lost when the expression of different autophagy genes is reduced, implicating that its effects are not mediated by autophagy-independent processes (like mild translation suppression). Also, the mTOR-independent autophagy enhancers have no effects on mutant protein clearance in autophagy-deficient cells. In this review, we describe various drugs and pathways inducing autophagy, which may be potential therapeutic approaches for HD and related conditions.

Integrity signals

Registry

Crossref · 10.1038/cdd.2008.110

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sarkar, S., Ravikumar, B., Floto, R. A., & Rubinsztein, D. C.
Affiliations
University of Cambridge (GB)
Corresponding author
Rubinsztein, D C
Venue
Cell Death & Differentiation
Published
2008-07-18
Volume
16
Issue
1
Pages
46-56
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W2062686313
Cited by
578
References
80
Citations by year
2026: 27 · 2025: 22 · 2024: 31 · 2023: 22 · 2022: 32 · 2021: 39 · 2020: 29 · 2019: 35 · 2018: 25 · 2017: 31 · 2016: 41 · 2015: 31 · 2014: 40 · 2013: 43 · 2012: 31
FWCI
3.52
Type
journal article
Language
en
Open access
closed
Locations
  • Cell Death and Differentiation (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Funders
  • Wellcome Trust (064354)
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • National Institute for Health and Care Research
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
rapamycin, mTOR-independent autophagy, autophagy inducers, Huntington's disease, protein aggregation, neurodegenerative diseases, Drosophila model, therapeutic target
MeSH terms
Huntingtin Protein, Animals, Antibiotics, Antineoplastic, Autophagy, Disease Models, Animal, Drosophila, Gene Expression Regulation, Humans, Mutation, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Protein Kinases, Protein Biosynthesis, Signal Transduction, Neurodegenerative Diseases, Sirolimus, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review